Its role in cGvHD is highly documented as recipients of icos(−/−) CD4+ T cells exhibited less GVHD morbidity (70) with a significant decrease in donor T follicular helper population, Th17 skewing, and lower antibody production (71). This evidence concerns the gene CD4 and graft versus host disease.